The Mild Cognitive Impairment drugs in development market research report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mild Cognitive Impairment. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued products.

GlobalData tracks 49 drugs in development for Mild Cognitive Impairment by 45 companies/universities/institutes. The top development phase for Mild Cognitive Impairment is phase ii with 17 drugs in that stage. The Mild Cognitive Impairment pipeline has 46 drugs in development by companies and three by universities/ institutes. Some of the companies in the Mild Cognitive Impairment pipeline products market are: CuraSen Therapeutics, KeifeRx and AgeneBio.

The key targets in the Mild Cognitive Impairment pipeline products market include Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP), Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT), and 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A).

The key mechanisms of action in the Mild Cognitive Impairment pipeline product include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT) Inhibitor with three drugs in Phase III. The Mild Cognitive Impairment pipeline products include eight routes of administration with the top ROA being Oral and nine key molecule types in the Mild Cognitive Impairment pipeline products market including Small Molecule, and Monoclonal Antibody.

Mild Cognitive Impairment overview

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol.

For a complete picture of Mild Cognitive Impairment’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.